Search results
Results from the WOW.Com Content Network
When examining the cost-effectiveness of statin use in older adults, the researchers report that statins were cost-effective, with the cost per quality-adjusted life years gained below £3,502 ...
In 2016, NICE set the cost-per-QALY threshold at £100,000 for treatments for rare conditions because, otherwise, drugs for a small number of patients would not be profitable. [3] The use of ICERs therefore provides an opportunity to help contain health care costs while minimizing adverse health consequences. [ 4 ]
[65] [64] Statin-induced rhabdomyolysis is rare, occurring in less than 0.1% of people who take statins. [66] [67] [68] Statin induced rhabdomyolysis, as with other statin associated muscle symptoms, occurs most commonly in the first year of treatment but can occur at any time during treatment. [66]
Medical care ratio (MCR), also known as medical cost ratio, medical loss ratio, and medical benefit ratio, is a metric used in managed health care and health insurance to measure medical costs as a percentage of premium revenues. [1]
Statins are a medication type that can help people at risk for atherosclerotic cardiovascular disease. Doctors look at several factors to determine if statin therapy makes the most sense for ...
This incremental cost-effectiveness ratio (ICER) can then be used to allocate healthcare resources, often using a threshold approach. [ 8 ] In the United Kingdom , the National Institute for Health and Care Excellence (NICE), which advises on the use of health technologies within the National Health Service , used "£ per QALY" to evaluate ...
Rosuvastatin, sold under the brand name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. [6] It is recommended to be used together with dietary changes, exercise, and weight loss. [6] It is taken orally (by mouth). [6]
The rate at which such events occur has been widely debated, in part because the risk/benefit ratio of statins in low-risk populations is highly dependent on the rate of adverse events. [ 71 ] [ 72 ] [ 73 ] A Cochrane meta-analysis of statin clinical trials in primary prevention found no evidence of excess adverse events among those treated ...